Tefibazumab is a humanized monoclonal antibody (IgG1) against the clumping factor A (ClfA) of *Staphylococcus aureus*. Tefibazumab shows a pharmacokinetic (PK) behavior which is typical for an antibody without endogenous target.  

The herein presented evaluation report evaluates the performance of the physiologically based pharmacokinetic (PBPK) model for tefibazumab in healthy adults. 

The presented Tefibazumab PBPK model as well as the respective evaluation plan and evaluation report are provided open-source (https://github.com/.../Compound-model).

